Investment Rating - The report suggests a cautious subscription for the company [1][4]. Core Insights - The company is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent individuals with a disposable income exceeding RMB 200,000 [2]. - The private mid-to-high-end healthcare service market in China is expected to grow significantly, with total revenue projected to increase from RMB 193 billion in 2020 to RMB 426 billion by 2024, representing a compound annual growth rate (CAGR) of 21.9% [3]. - The company operates 19 healthcare facilities across major Chinese cities, including 17 clinics and 2 hospitals, and is positioned as the third-largest private mid-to-high-end healthcare service provider in China with a market share of 2.0% [2][3]. Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 690 million and RMB 959 million, respectively, with a net profit of RMB 80.2 million expected in 2024 [4]. - For the first eight months of 2025, the company has already achieved a revenue of RMB 696 million, reflecting a year-on-year growth of 14.0% [4]. - The estimated market capitalization post-IPO is between HKD 3.715 billion and HKD 4.288 billion, with a price-to-earnings (PE) ratio of 26-31 times, indicating a relatively high valuation considering the company's growth potential [4].